Therapeutic HPV vaccines deliver the oncogenic proteins to immune cells, enhancing the immune response of CD8+ cytotoxic T cells against HPV+ penile cancer (36), with promising prospects for application. The gene discussed is CD8A; the disease is penile cancer.